— Know what they know.
Not Investment Advice

RPRX NASDAQ

Royalty Pharma plc
1W: -1.8% 1M: -9.4% 3M: +0.4% YTD: +47.9% 1Y: +58.2% 3Y: +127.9% 5Y: +70.8%
$57.16
-0.47 (-0.82%)
 
Weekly Expected Move ±3.2%
$53 $55 $57 $59 $61
NASDAQ · Healthcare · Medical - Pharmaceuticals · Tech Score Sell · Power 40 · $25.3B mcap · 415M float · 0.803% daily turnover · Short 44% of daily vol

Cash Flow Trends

Operating Cash Flow
$2.5B -10.1% ▼
5Y CAGR: +4.1%
Capital Expenditures
$0 +0.0% ▲
Free Cash Flow
$2.5B -10.1% ▼
5Y CAGR: +4.1%
Dividends Paid
$378M -0.5% ▼
Buybacks
$1.2B -434.5% ▼
Net Change in Cash
-$310M -168.7% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income$1.2B$230M$1.7B$1.3B$1.3B
Depreciation & Amort.$23M$6M$0$0$4M
Stock-Based Comp.$2M$2M$2M$2M$290M
Change in Working Capital-$16M$33M$5M$53M-$17M
Other Non-Cash Items$767M$1.9B$1.3B$1.4B$889M
Operating Cash Flow$2.0B$2.1B$3.0B$2.8B$2.5B
— Investing Activities —
Capital Expenditures$0$0$0$0$0
Acquisitions (Net)-$35M-$10M-$13M-$11M-$74M
Investment Purchases-$3.6B-$2.6B-$2.1B-$2.7B-$1.9B
Investment Sales$1.8B$1.5B$26M$118M$567M
Other Investing-$18M$0$29M-$49M-$175M
Investing Cash Flow-$1.9B-$1.0B-$2.1B-$2.7B-$1.6B
— Financing Activities —
Net Debt Issuance$1.3B$0-$1.0B$1.5B$954M
Stock Repurchased$0$0-$305M-$230M-$1.2B
Dividends Paid-$285M-$333M-$358M-$376M-$378M
Other Financing-$602M-$612M-$486M-$504M-$535M
Financing Cash Flow$385M-$945M-$2.1B$361M-$1.2B
Net Change in Cash$532M$170M-$1.2B$452M-$310M
Cash End of Period$1.5B$1.7B$477M$929M$619M
Free Cash Flow$2.0B$2.1B$3.0B$2.8B$2.5B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms